Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

Rhea-AI Summary

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that its President and CEO, Bobak Azamian, will present a corporate update at the Virtual Credit Suisse 30th Annual Healthcare Conference.

The presentation is scheduled for November 8th at 11:40 AM PT / 2:40 PM ET. Interested parties can view the webcast on the company's website, with a replay available within 48 hours. Tarsus focuses on innovative treatments in eye care, including its lead candidate TP-03, currently in a Phase 3 trial for Demodex blepharitis and Meibomian Gland Disease.

IRVINE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus will present a corporate update at the Virtual Credit Suisse 30^th Annual Healthcare Conference.

Presentation Details
Date: Monday, November 8^th
Time: 11:40am PT / 2:40pm ET
Webcast: Tarsus Credit Suisse Webcast

The above listed date is subject to change. Details on the presentation time or changes to the presentation date can be found on the Company's website. Please check www.tarsusrx.com for the latest information.

A live webcast of the presentation will also be available on the events section of the Tarsus website. The replay will be available within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.

Contacts:
Media Contact:
SuJin Oh
Shop PR
(917) 841-5213
sujin@shop-pr.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When will Tarsus Pharmaceuticals present at the Credit Suisse Annual Healthcare Conference?

Tarsus Pharmaceuticals will present on November 8th, 2021, at 11:40 AM PT / 2:40 PM ET.

Who is presenting for Tarsus Pharmaceuticals at the conference?

Bobak Azamian, M.D., Ph.D., President and CEO of Tarsus Pharmaceuticals, will present.

How can I access the Tarsus Pharmaceuticals presentation?

The presentation can be accessed via a live webcast on the Tarsus website.

What is TP-03 and its significance to Tarsus Pharmaceuticals?

TP-03 is Tarsus's lead product candidate, currently in a Phase 3 pivotal trial for treating Demodex blepharitis.

What other therapeutic areas is Tarsus Pharmaceuticals focusing on?

In addition to eye care, Tarsus is developing treatments in dermatology and infectious disease prevention.